参考文献/References:
[1] Abifadel M,Varret M,Rabes JP,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet,2003,34(2):154-156.[2] Goldstein JL,Brown MS. The LDL receptor[J]. Arterioscler Thromb Vasc Biol,2009,29(4):431-438.[3] Lekuona I. PCSK9 inhibitors:from innovation to sustainable clinical application[J]. Rev Esp Cardiol (Engl Ed),2018,71(12):996-998.[4] Tang ZH,Peng J,Ren Z,et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway[J]. Atherosclerosis,2017,262:113-122.[5] Ding Z,Pothineni NVK,Goel A,et al. PCSK9 and inflammation:role of shear stress,pro-inflammatory cytokines,and LOX-1[J]. Cardiovasc Res,2020,116(5):908-915.[6] Hoogeveen RM,Opstal TSJ,Kaiser Y,et al. PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers[J]. JACC Cardiovasc Imaging,2019,12(12):2571-2573.[7] Dozio E,Ruscica M,Vianello E,et al. PCSK9 expression in epicardial adipose tissue:molecular association with local tissue inflammation[J]. Mediators Inflamm,2020,2020:1348913.[8] Landlinger C,Pouwer MG,Juno C,et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation,and atherosclerosis in APOE*3Leiden.CETP mice[J]. Eur Heart J,2017,38(32):2499-2507.[9] Hovland A,Retterstol K,Mollnes TE,et al. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs:an unused potential?[J]. Scand Cardiovasc J,2020,54(5):274-279.[10] Luquero A,Badimon L,Borrell-Pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation[J]. Front Cardiovasc Med,2021,8:639727.[11] Wu CY,Tang ZH,Jiang L,et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J]. Mol Cell Biochem,2012,359(1-2):347-358.[12] Cicero AFG,Toth PP,Fogacci F,et al. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors[J]. Nutr Metab Cardiovasc Dis,2019,29(5):527-529.[13] Leucker TM,Gerstenblith G,Schar M,et al. Evolocumab,a PCSK9-monoclonal antibody,rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia[J]. J Am Heart Assoc,2020,9(14):e016263.[14] Grune J,Meyborg H,Bezhaeva T,et al. PCSK9 regulates the chemokine receptor CCR2 on monocytes[J]. Biochem Biophys Res Commun,2017,485(2):312-318.[15] Bernelot Moens SJ,Neele AE,Kroon J,et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia[J]. Eur Heart J,2017,38(20):1584-1593.[16] Sun J,Lepor NE,Canton G,et al. Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab[J]. Int J Cardiovasc Imaging,2021,37(4):1415-1422.[17] Cheng JM,Oemrawsingh RM,Garcia-Garcia HM,et al. PCSK9 in relation to coronary plaque inflammation:Results of the ATHEROREMO-IVUS study[J]. Atherosclerosis,2016,248:117-122.[18] Kong Q,Liu M,Li Y,et al. Effect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS[J]. Ann Palliat Med,2020,9(5):3078-3088.[19] Pan Y,Zhou Y,Wu H,et al. A therapeutic peptide vaccine against PCSK9[J]. Sci Rep,2017,7(1):12534.[20] Wu D,Pan Y,Yang S,et al. PCSK9Qβ-003 vaccine attenuates atherosclerosis in apolipoprotein E-deficient mice[J]. Cardiovasc Drugs Ther,2021,35(1):141-151.[21] Qi Z,Hu L,Zhang J,et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation,thrombosis,and myocardial infarct expansion by binding to platelet CD36[J]. Circulation,2021,143(1):45-61.[22] Navarese EP,Kolodziejczak M,Winter MP,et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor:the PCSK9-REACT study[J]. Int J Cardiol,2017,227:644-649.[23] Barale C,Bonomo K,Frascaroli C,et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody:a 12-month follow-up[J]. Nutr Metab Cardiovasc Dis,2020,30(2):282-291.[24] Cammisotto V,Baratta F,Castellani V,et al. Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways[J]. Int J Mol Sci,2021,22(13):7193.[25] Marston NA,Gurmu Y,Melloni GEM,et al. The Effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism[J]. Circulation,2020,141(20):1600-1607.[26] Schwartz GG,Steg PG,Szarek M,et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome:role of lipoprotein(a) and modification by alirocumab:prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial[J]. Circulation,2020,141(20):1608-1617.[27] Jacome Sanz D,Raivola J,Karvonen H,et al. Evaluating targeted therapies in ovarian cancer metabolism:novel role for PCSK9 and second generation mTOR inhibitors[J]. Cancers (Basel),2021,13(15):3727.[28] Xu B,Li S,Fang Y,et al. Proprotein convertase subtilisin/kexin type 9 promotes gastric cancer metastasis and suppresses apoptosis by facilitating MAPK signaling pathway through HSP70 up-regulation[J]. Front Oncol,2020,10:609663.[29] Zhang SZ,Zhu XD,Feng LH,et al. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma[J]. Exp Hematol Oncol,2021,10(1):25.[30] Liu X,Bao X,Hu M,et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer[J]. Nature,2020,588(7839):693-698.[31] Momtazi-Borojeni AA,Nik ME,Jaafari MR,et al. Effects of immunization against PCSK9 in an experimental model of breast cancer[J]. Arch Med Sci,2019,15(3):570-579.[32] Momtazi-Borojeni AA,Nik ME,Jaafari MR,et al. Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer[J]. Arch Med Sci,2019,15(3):559-569.[33] Boyd JH,Fjell CD,Russell JA,et al. Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis[J]. J Innate Immun,2016,8(2):211-220.[34] Walley KR,Thain KR,Russell JA,et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome[J]. Sci Transl Med,2014,6(258):258ra143.[35] Mitchell KA,Moore JX,Rosenson RS,et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort[J]. PLoS One,2019,14(2):e0210808.[36] Feng Q,Wei WQ,Chaugai S,et al. A genetic approach to the association between PCSK9 and sepsis[J]. JAMA Netw Open,2019,2(9):e1911130.[37] Momtazi AA,Banach M,Sahebkar A. PCSK9 inhibitors in sepsis:a new potential indication?[J]. Expert Opin Investig Drugs,2017,26(2):137-139.[38] Gan ES,Tan HC,Le DHT,et al. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes[J]. J Clin Invest,2020,130(10):5223-5234.[39] Arama C,Diarra I,Kouriba B,et al. Malaria severity:possible influence of the E670G PCSK9 polymorphism:a preliminary case-control study in Malian children[J]. PLoS One,2018,13(2):e0192850.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(2):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(2):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[3]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(2):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[4]孟凡华 付真彦.一种新型的治疗血脂异常的干扰RNA药物Inclisiran[J].心血管病学进展,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
MENG Fanhua,FU Zhenyan.Inclisiran, A New Small Interfering RNA Drug for the Treatment of Dyslipidemia[J].Advances in Cardiovascular Diseases,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
[5]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(2):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[6]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(2):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[7]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(2):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[8]王兰 叶玉兰 宁明安 张迪 尚粉青.血清PCSK9水平与PCI后冠状动脉病变再进展的关系研究[J].心血管病学进展,2022,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Lan,YE Yulan,NING Mingan,et al.Correlation Analysis Between Serum PCSK9 Level and Coronary Artery Pathological ?Progression After PCI[J].Advances in Cardiovascular Diseases,2022,(2):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[9]白宏晔 甘辉立.呼吸系统疾病在他汀类药物多效性中的获益[J].心血管病学进展,2022,(9):824.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.014]
BAI Hongye,GAN Huili.Benefits of Respiratory Disease in Pleiotropy of Statins[J].Advances in Cardiovascular Diseases,2022,(2):824.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.014]
[10]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(2):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]